Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABSK112 |
| Synonyms | |
| Therapy Description |
ABSK112 is an EGFR inhibitor with selectivity for exon 20 insertion mutations, which potentially decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): LB327). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABSK112 | EGFR Exon 20 Insertion Inhibitor 15 EGFR Inhibitor (Pan) 63 | ABSK112 is an EGFR inhibitor with selectivity for exon 20 insertion mutations, which potentially decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): LB327). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06225804 | Phase I | ABSK112 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | Recruiting | USA | 1 |